/[corp]/sql/news.txt
This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Contents of /sql/news.txt

Parent Directory Parent Directory | Revision Log Revision Log


Revision 1.1.1.1 - (show annotations) (vendor branch)
Thu Mar 15 07:51:20 2001 UTC (23 years, 4 months ago) by dpavlin
Branch: DbP, MAIN
CVS Tags: r1, HEAD
Changes since 1.1: +0 -0 lines
File MIME type: text/plain
initial import

1 50 PLIVA and Microsoft sign global purchasing agreement</a></b><br>
2 <i>Zagreb, 18 January 2001.</i><br>
3 PLIVA and Microsoft signed the Microsoft Enterprise
4 Agreement - an agreement lasting several years which enables PLIVA to standardise
5 Microsoft technology on its computers in facilities in Croatia and throughout Central
6 and Eastern Europe.
7
8 49 PLIVA acquires Dominion</a></b><br>
9 <i>Zagreb, 19 December 2000.</i><br>
10 PLIVA d.d. (&quot;PLIVA&quot;) announced today that is has acquired Pharmascience UK
11 Limited, 100% owner of Dominion Pharma Limited (&quot;Dominion&quot;), for
12 a total cash consideration of GBP 3.4 million.
13
14 48 PLIVA and Zagrebacka banka Agreement</a></b><br>
15 <i>Zagreb, 19 December 2000.</i><br>
16 PLIVA d.d. (PLIVA) and Zagrebacka banka (ZABA) today announced that they have
17 reached an agreement regarding the sale of ZABA's 2.5% equity stake in PLIVA.
18
19 47 VETERINA d.o.o. Established</a></b><br>
20 <i>Zagreb, 8 December 2000.</i><br>
21 Based on strategic orientation to pharmaceuticals as its core business, PLIVA has
22 decided to spin off its Animal Health &amp; Agrochemicals business segment into an
23 independent company in its full ownership.
24
25 46 Engineer from PLIVA wins golden award for innovation</a></b><br>
26 <i>Zagreb, 8 December 2000.</i><br>
27 PLIVA's employee Srecko Brkic, a mechanical engineer in Technical Operations, won
28 the golden award at the 49th World Fair of Innovation, Research and New Technologies
29 EUREKA 2000
30
31 45 Simplified customs procedures for the company</a></b><br>
32 <i>Zagreb, 8 December 2000.</i><br>
33 Today PLIVA started implementing simplified customs procedures, granted to the company
34 as part of a pilot-project by the Customs Administration of the Republic of Croatia.
35
36 44 PLIVA ’s R&D Day in London on November 29, 2000 Balanced Portfolio for Short, Medium and Long Term Growth</a></b><br>
37 <i>Zagreb, 29 November 2000.</i>
38
39 43 PLIVA signs USD 85 m Credit Facility Agreement with EBRD and IFC</a></b><br>
40 <i>Zagreb, 20 November 2000.</i><br>
41 PLIVA d.d.(PLIVA) today announced that it signed a credit facility agreement
42 (The Agreement) with the European Bank for Reconstruction and Development (EBRD)
43 and the International Finance Corporation (IFC) on 17 November 2000.
44
45 42 PLIVA's subsidiary NEVA d.o.o. obtains the ISO 14001 environmental management system certification</a></b><br>
46 <i>Zagreb, 15 November 2000.</i><br>
47 In the presence of Mr. Roland Zuvanic, Deputy Minister of Environmental Protection
48 and Zoning, and Mr. Zeljko Covic, President of the Management Board and CEO of PLIVA,
49 Mr. Leonardo Omodeo-Zorini, representative of the Norwegian certification company DNV
50 presented the certificate to NEVA's director Ms. Sanja Slunjski.
51
52 41 Encouragement to young scientists</a></b><br>
53 <i>Zagreb, 14 November 2000.</i><br>
54 On 14 November 2000 PLIVA and the Croatian Chemical Society presented
55 the Organic Chemistry Award Vladimir Prelog for the fourth time. This year
56 the award was presented to Valerije Vrcek, Ph.D., a young scientist from
57 the Faculty of Pharmacy and Biochemistry in Zagreb.
58
59 40 State and business delegation from Turkey visits PLIVA</a></b><br>
60 <i>Zagreb, 28 September 2000.</i><br>
61 A state and business delegation from Turkey was in an official visit to Zagreb from 26 to 28
62 September 2000. The delegation was led by Minister of Health of the Republic of Turkey, Mr. Osman Durmus.
63
64 39 PLIVA divests Lachema's non-core operations in Blansko</a></b><br>
65 <i>Zagreb, 11 September 2000.</i><br>
66 PLIVA d.d. ('PLIVA') announced today that it has signed an agreement with Synthon s.r.o.,
67 subsidiary of the Dutch firm Synthon BV, regarding the sale of Lachema's
68 non-core operations in Blansko, Czech Republic.
69
70
71 38 A New Mandate for the Members of PLIVA's MB</a></b><br>
72 <i>Zagreb, 7 September 2000.</i><br>
73 As the mandates of PLIVA's Management Board members are expiring, the company's
74 Supervisory Board appointed the Management Board members for a new five-year period.
75
76 37 PLIVA's Scientists - Heroes of Chemistry</a></b><br>
77 <i>Zagreb, 20 August 2000.</i><br>
78 The &quot;Heroes of Chemistry
79 2000&quot;ceremony was held on 20 August 2000 in Washington D.C., USA, organised
80 by the American Chemical Society (ACS), a non-profit association of American
81 chemists and chemical engineers and the largest association of scientists in the
82 world.
83
84 36 Special Announcement</a></b><br>
85 <i>Zagreb, 18 July 2000.</i><br>
86 We would like to inform you that
87 PLIVA's annual summer holiday will last from July 24th to August 14th.
88
89 35 PLIVA to reduce workforce by the end of 2000</a></b><br>
90 <i>Zagreb, 3 July 2000.</i><br>
91 PLIVA d.d. ('PLIVA') announced today that it will significantly reduce its total
92 workforce by the end of the year.
93
94 34 PLIVA's Annual General Meeting</a></b><br>
95 <i>Zagreb, 8 June 2000.</i><br>
96 The General Assembly of PLIVA d.d. shareholders was held today. The PLIVA Management Board presented Company's 1999
97 operations and position, while the Supervisory Board gave a presentation on
98 their monitoring of the Company's management of affairs.
99
100 33 PLIVA Granted License for an Anti-Fungal NCE by BAYER AG</a></b><br>
101 <i>Zagreb, 23 May 2000.</i><br>
102 PLIVA d.d. ('PLIVA') announced today that it has received a license
103 for a new chemical entity for the treatment of fungal infections from
104 BAYER AG, Germany, a compound in its final stage of pre-clinical
105 trials.
106
107 32 Chinese Minister of Health Visits PLIVA</a></b><br>
108 <i>Zagreb, 20 May 2000.</i><br>
109 A high-level delegation headed by Mr. Zhang Wenkang, Minister of Health of
110 The People's Republic of China, is visiting Croatia. The Mr. Wenkang's
111 visit has been organised by the Croatian Ministry of Health and the
112 Chinese Embassy.
113
114 31 Additional Stake Acquired in Lachema</a></b><br>
115 <i>Zagreb, 27 April 2000.</i><br>
116 PLIVA announced today that it has
117 signed an agreement with an institutional investor for the purchase of 26.08% of
118 the total share capital of Lachema, the Czech pharmaceutical company, for cash
119 consideration of USD 4,945,308.49.
120
121 30 PLIVA Group 1999 Full Year Results</a><br>
122 <i>Zagreb, 23 March 2000.<br>
123 With a 26.2% growth in net
124 income to HRK 869.1 m, PLIVA achieved strong operating results in 1999,
125 despite unfavourable conditions in the surrounding region.
126
127 29 PLIVA sells 75% stake in its Yeast Subsidiary<br>
128 </b><i>Zagreb, March 1, 2000.</i><br>
129 PLIVA d.d. ('PLIVA') announced that it has signed an
130 agreement to sell its yeast operations carried out through its Croatian
131 subsidiary SAF Kvasac d.o.o. to Cie des Levures Lesaffre, today’s world leader
132 in the production of yeast and yeast extracts.
133
134 28 New drug forms and prices</a><br>
135 </b><i>Zagreb, 15 February 2000.</i><br>
136 The Croatian Institute
137 for Health Insurance has announced its reimbursment list as of 15 February 2000.
138 This includes five new drug forms produced by PLIVA
139
140 27 PLIVA ups stake in PLIVA Krakow</a><br>
141 </b><i>Zagreb, December 16, 1999.</i><br>
142 PLIVA today announced that it has acquired
143 an additional 6.17 per cent share capital of PLIVA Krakow S.A. from
144 Handlowy Investments S.A., for a cash consideration of USD 16,008,726.29.
145
146 26 Management Board Changes</a><br>
147 </b><i>Zagreb, December 9, 1999.</i><br>
148 The organisational changes resulting from the PLIVA XXI project and the
149 further internationalisation of the Company’s activities entail changes
150 in the roles and responsibilities of the members of the Management Board.
151
152 25 Y2k Preparations</a><br>
153 <i>Zagreb, 6 December 1999.<br>
154 We at PLIVA
155 d.d. are fully aware of the need for Y2k compliance to avoid any business
156 disruption associated with computer software, hardware and embedded
157 systems that are incapable of managing dates beyond the year 1999.
158
159 24 Lachema Acquisition Finalised</a><br>
160 </b><i>Zagreb, December 3, 1999.</i><br>
161 PLIVA today announced that the acquisition of 66,67% stake of the Czech pharmaceutical
162 company, Lachema, was completed yesterday when PLIVA Krakow, PLIVA’s
163 subsidiary paid agreed price of USD 26.5 million.
164
165 23 PLIVA Acquires Czech Lachema</a><br>
166 <i>Zagreb, 12 November 1999.<br>
167 </i>PLIVA
168 has announced that it has signed agreements for the purchase of a 66.67%
169 stake in Lachema, the Czech pharmaceutical company, for a cash
170 consideration of USD 26.5 million from the company’s institutional
171 investors.
172
173 22 Notice to PLIVA d.d. Shareholders</a><br>
174 <i>Zagreb, 26 October 1999.<br>
175 </i>According
176 to the decision of the General Assembly of PLIVA d.d. shareholders held on 03
177 June 1999 concerning distribution of dividends to shareholders, PLIVA d.d.
178 should pay the 1998 dividend not later than 31 December 1999.
179
180 21 Predrag Novak Receives Phys. Chem. Award</a><br>
181 <i>Zagreb, 26 October 1999.<br>
182 The
183 award presented each year by the Croatian Chemical Society for
184 achievements in the field of physical chemistry was presented to Predrag
185 Novak, Ph.D., who works in PLIVA’s Research Institute, at a ceremony
186 held at the Rudjer Boskovic Institute on Tuesday, October 19th.
187
188
189 20 PLIVA Facilities Pass FDA Inspection</a><br>
190 </b><i>Zagreb, 27 October 1999.</i><br>
191 PLIVA’s new Azithromycin facility was found to be in compliance with good
192 manufacturing practice according to the Food and Drug Administration (FDA) inspection carried out
193 in mid-October of 1999.
194
195
196 19 Virlix® Price Approval Application at PLIVA-Krakow.</a><br>
197 <i>Zagreb, 14 October 1999.<br>
198 PLIVA Krakow has applied for price approval of the drug Virlix®
199 10mg*20tab. (cetirizine) which will replace the product Zyrtec®
200 10mg*20tab. (cetirizine) in PLIVA Krakow’s product portfolio.
201
202 18 Successful Debt Collection and the VAT</a><br>
203 </b><i>Zagreb, 14 October 1999.</i><br>
204 As
205 a result of a restrictive sales policy and higher collection from the
206 healthcare sector, in the last three months, PLIVA has recorded a decrease
207 in receivables from the Croatian healthcare sector, from HRK 613 million
208 at the end of June 1999 to HRK 400 million to date.
209
210 17 Vladimir Prelog Organic Chemistry Award.</a><br>
211 </b><i>Zagreb, 14 October 1999.</i><br>
212 The “Vladimir Prelog Organic Chemistry Award” was established in 1996 as a
213 means to encourage young Croatian scientists in the field of organic
214 chemistry. Its founders were PLIVA d.d. and the Croatian Chemical Society.
215
216 16 PLIVA CEO, Zeljko Covic, named 1999 Emerging Markets CEO of the Year</a><br>
217 </b><i>Zagreb, 28 September 1999.<br>
218 The selection Committee for the 1999 Emerging Markets CEO of the Year
219 Awards has selected Zeljko Covic, President of PLIVA's Management
220 Board, and PLIVA, as the Europe, Middle East and Africa Award
221 winner.
222 15 PLIVA GROUP RESULTS FOR 1H 1999.</a><br>
223 <i>Zagreb, 16 September, 1999.</i><br>
224 Despite challenges in the operating environment (Kosovo crisis,
225 the introduction of<span style="mso-spacerun: yes">&nbsp; </span>a
226 reference price system and illiquidity in the Croatian health-care
227 sector, introduction of a new health-care system in Poland and the
228 continuation of the Russian crisis), PLIVA achieved good results in
229 the first six months.
230 14 Organisational Changes</a></b><br>
231 <i>Zagreb, 1st July 1999.</i><br>
232 In response to changes in the environment, and with the aim
233 of generating long-term growth, PLIVA has defined a new strategy
234 within the activities of its PLIVA XXI project. The strategy is
235 based on pharmaceuticals being the core-business, continuously
236 increasing R&amp;D investments and intensifying the
237 internationalisation of the company.
238 13 Continued Strong Growth of Zithromax (Azithromycin) Sales</a><br>
239 </b><i>Zagreb, 20th April 1999.</i><b><br>
240 </b>&quot;Global sales of Zithromax (azithromycin), a broad-spectrum
241 oral antibiotic increased by 44 percent to US$ 441 million in the
242 first quarter of 1999&quot;, Pfizer reported last week. &quot;Growth
243 in sales resulted form physicians' increasing recognition of the
244 product's broad efficacy, compliance advantages, favourable
245 side-effect profile and, in liquid formulation for children, a
246 pleasant taste. Zithromax continues to be the most prescribed
247 brand-name prescription antibiotic in the U.S,&quot; added Pfizer in
248 its Press Release.
249 12 PLIVA announces acquisition of MIXIS GENETICS Ltd.</a><br>
250 </b><i>Zagreb, 15th April 1999.</i><b><br>
251 </b>PLIVA, the largest pharmaceuticals company in Central and
252 Eastern Europe announces that it has acquired 100% ownership of the
253 company MIXIS GENETICS Ltd. (&quot;MIXIS&quot;) for US$ 3.3 million.
254 By this transaction PLIVA becomes the owner of several patents
255 covering break-through technologies in the field of biodiversity.
256 11 PLIVA GROUP 1998 FULL YEAR RESULTS</a><br>
257 </b><i>Zagreb, 12th April 1999.</i><b><br>
258 </b>PLIVA, the largest pharmaceuticals company in Central and
259 Eastern Europe and listed on the London and Zagreb Stock Exchanges,
260 today announces excellent full year results for the financial year
261 1998.
262 10 PLIVA AND THE ALTHEXIS COMPANY ANNOUNCE A COLLABORATION ON THE STRUCTURE-BASED DRUG DESIGN OF NOVEL BROAD SPECTRUM ANTIBIOTICS</a><br>
263 </b><i>Zagreb, 8th February 1999.</i><b><br>
264 </b>PLIVA d.d., Zagreb, Croatia and The Althexis Company, Inc.,
265 Boston, MA., USA, today announced that they have entered into a
266 collaboration to develop and commercialise novel broad spectrum
267 antibiotics using structure-based drug design (&quot;SBDD&quot;)
268 technologies. PLIVA support for the Althexis program may total $14.4
269 million over three years in research funding and milestone payments.
270 Additional future revenues to Althexis and PLIVA may result from
271 certain exclusive marketing rights each retains under the
272 collaboration agreement.
273 9 PLIVA d.d. ANNOUNCES JOINT RESEARCH VENTURE WITH GLAXO WELLCOME PLC TO FIND NEW ANTIBIOTICS TO BEAT TREATMENT RESISTANCE</a><br>
274 </b><i>Zagreb, 1st February 1999.</i><b><br>
275 </b>PLIVA, the largest pharmaceutical company from Central and
276 Eastern Europe, announces that they are today signing a Memorandum
277 of Understanding with the UK-based pharmaceutical company, Glaxo
278 Wellcome plc, for a research collaboration aimed at finding the next
279 generation of macrolide antibiotics, capable of overcoming the
280 growing problem of treatment resistance.
281 8 INTRODUCING A REFERENCE PRICE SYSTEM FOR PHARMACEUTICAL PRODUCTS IN CROATIA AND ITS INFLUENCE ON PLIVA'S BUSINESS PERFORMANCE</a><br>
282 </b><i>Zagreb, 20 January 1999.</i><b><br>
283 </b>Prompted by the Ministry of Health, the Croatian Institute for
284 Health Insurance (&quot;HZZO&quot;) has announced its intention to
285 introduce, as of 01 February 1999, a system of so-called reference
286 prices for all pharmaceutical products reimbursed by state health
287 insurance. Accordingly, PLIVA d.d. (&quot;PLIVA&quot;), the largest
288 pharmaceutical company in Croatia and leading pharmaceutical group
289 in Central and Eastern Europe, has commenced negotiations with the
290 Ministry of Health and HZZO about determining new prices of drugs.
291 7 PLIVA LAUNCHES NEW STRATEGY FOR THE 21st CENTURY</a><br>
292 </b><i>Zagreb, 17 December 1998.</i><b><br>
293 </b>PLIVA’s new vision and new strategy represents the company’s
294 response to the challenges that globalisation is setting before
295 pharmaceutical companies. At the same time, it represents an
296 adjustment to the times and circumstances which characterise this
297 industry at the end of the 90’s and will depict the trends in the
298 next decade.
299
300 6 PLIVA TO BUY POLISH PHARMACEUTICAL COMPANY FARMACOM</a><br>
301 </strong><i>Zagreb, 14 December 1998.</i><strong><br>
302 The Memorandum of Understanding deals with PLIVA's
303 intention to purchase a 60% stake in the Polish pharmaceutical
304 company FARMACOM whose head office is situated in Krakow, Poland.
305 5 <strong>POLFA KRAKOW CHANGES NAME TO PLIVA KRAKOW</strong></a><br>
306 <i>Zagreb, 14 December 1998.</i><br>
307 POLFA Krakow’s General Assembly decided to change the name of the
308 company at its meeting held on 30 November 1998. The new name -
309 PLIVA Krakow - will be officially used after completion of legal
310 procedures dealing with the registration which will be carried out
311 at the Polish court with jurisdiction over the matter.
312
313 4 <strong>PLIVA AND PRIVREDNA BANKA ZAGREB SIGN COMMERCIAL PAPER CONTRACT</strong></a><br>
314 <i>
315 Zagreb, 11th December 1998.</i>
316 On 11 December 1998,
317 PLIVA, the leading pharmaceutical company from Central and Eastern
318 Europe, signed a contract with Privredna banka Zagreb for issuing
319 and selling PLIVA’s commercial papers on the Croatian money
320 market. The contract defines a HRK 400 million commercial paper
321 programme.
322
323 3 <strong>PLIVA SIGNS A USD 100 MILLION WORTH EURO-COMMERCIAL PAPER PROGRAM</strong></a><br>
324 Zagreb, 4th December 1998</i><i>.</i>
325 <br>
326 PLIVA, the largest
327 pharmaceutical company from Central and Eastern Europe signs a USD
328 100 million worth Euro-commercial paper program and gain
329 access to the debt marketIn Vienna on Friday 4 December, PLIVA
330 signed a contract with six European banks which allows it to issue
331 Euro commercial papers up to USD 100 million on the Euro market.
332 2 RESPONSE TO SPECULATION RELATING TO LEK
333 Zagreb, 5th October 1998
334 PLIVA, the largest
335 pharmaceutical company from CEE, today denied the press speculation
336 that it may be intending to make a hostile takeover bid for Lek, the
337 Slovenian pharmaceutical company based in Ljubljana.
338 1 PLIVA ACQUIRES WORLD-WIDE RIGHTS FOR A NEW COMPOUND WITH THROMBOPOIETIN-LIKE ACTIVITY
339 Zagreb, 7th September 1998.</small></i>
340 The action of the
341 compound is distinctly different from thrombopoietin and constitutes
342 a strong alternative or complement to thrombopoietin .
343
344 0 1998 HALF YEAR RESULTS - CONTINUED STRONG PERFORMANCE<br>
345 Zagreb, 4th September 1998.
346 OPERATING PROFIT UP BY 28.6% PLIVA, the largest pharmaceutical company in Central &amp;
347 Eastern Europe, listed on the London and Zagreb Stock Exchanges,
348 today announced excellent results for the first half of 1998.
349 -1 PLIVA OPENS NEW STATE-OF-THE-ART AZITHROMYCIN PRODUCTION FACILITY</b><br>
350 </a><i>Zagreb, 4th September 1998</i><i>.</i><br>
351 PLIVA, the largest pharmaceutical company in Central
352 and Eastern Europe, announces that its new Azithromycin production
353 plant has been completed. The project worth US$ 100 million is
354 PLIVA’s biggest investment in a production site to date. A major
355 part of the investment has been financed by PLIVA’s own funds.
356 -2 PLIVA ACQUIRES YEAST FACTORY IN SLOVAKIA</b><br>
357 </a><i>Zagreb, 4th September 1998</i><i>.<br>
358 PLIVA, the largest pharmaceutical company from Central and
359 Eastern Europe, announces the acquisition of Fermenta, joint stock
360 company in Trebišov, Slovakia (&quot;Fermenta&quot;). Fermenta, the
361 second biggest Slovakian yeast producer, was purchased for a cash
362 consideration of USD 1.3 million.
363
364 -3 SECONDARY OFFERING OF PLIVA SHARES:<br> </small><small>I</small><small><small>NSTITUTIONAL PRICE FIXED AT US$ 16.60 PER GDR</small><br> STRONG INTERNATIONAL AND DOMESTIC DEMAND SHOWN</small>
365 </b><i>Zagreb, 13th May 1998.</i><small><br>
366 The Croatian Ministry of Finance today announced the successful
367 completion of an offering of approximately 2.92 million shares
368 (which includes 12.37 million GDRs) of PLIVA
369 d.d. (“PLIVA”).
370 PLIVA
371 is the most profitable company in Croatia and the largest
372 pharmaceutical company headquarters in Central and Eastern Europe.
373 -4 PLIVA SIGNS AGREEMENT WITH WARNER-LAMBERT PHARMACEUTICAL RESEARCH TO LICENSE OUT GASTROINTESTINAL PEPTIDES
374 </b><i>Zagreb, 24th April, 1998.</i><b><br>
375
376 PLIVA, the largest pharmaceutical company in Central and Eastern
377 Europe has signed an agreement with Parke-Davis, a division of
378 Warner-Lambert Company. The agreement gives Parke-Davis an exclusive
379 option to license PLIVA’s newly discovered gastrointestinal
380 peptides.

  ViewVC Help
Powered by ViewVC 1.1.26